Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by LMR Partners LLP

LMR Partners LLP grew its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 235.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,824 shares of the medical device company's stock after purchasing an additional 23,743 shares during the period. LMR Partners LLP owned approximately 0.05% of Tandem Diabetes Care worth $1,434,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fred Alger Management LLC lifted its holdings in Tandem Diabetes Care by 45.2% in the second quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company's stock valued at $87,595,000 after acquiring an additional 677,036 shares during the period. Victory Capital Management Inc. boosted its holdings in Tandem Diabetes Care by 2,836.2% during the second quarter. Victory Capital Management Inc. now owns 403,370 shares of the medical device company's stock worth $16,252,000 after buying an additional 389,632 shares in the last quarter. Kingdon Capital Management L.L.C. grew its position in Tandem Diabetes Care by 153.9% during the first quarter. Kingdon Capital Management L.L.C. now owns 493,080 shares of the medical device company's stock valued at $17,460,000 after buying an additional 298,880 shares during the period. First Light Asset Management LLC increased its holdings in Tandem Diabetes Care by 49.1% in the second quarter. First Light Asset Management LLC now owns 708,482 shares of the medical device company's stock valued at $28,545,000 after buying an additional 233,405 shares in the last quarter. Finally, Brown Capital Management LLC grew its position in shares of Tandem Diabetes Care by 29.9% during the 1st quarter. Brown Capital Management LLC now owns 954,567 shares of the medical device company's stock valued at $33,801,000 after acquiring an additional 219,940 shares during the period.

Tandem Diabetes Care Trading Up 8.2 %

NASDAQ TNDM traded up $2.28 during trading on Wednesday, hitting $30.15. The stock had a trading volume of 2,057,374 shares, compared to its average volume of 1,606,723. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The company has a market capitalization of $1.98 billion, a PE ratio of -15.27 and a beta of 1.36. The firm has a 50 day moving average price of $36.93 and a 200 day moving average price of $41.50. Tandem Diabetes Care, Inc. has a twelve month low of $17.87 and a twelve month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. The business had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company's revenue for the quarter was up 31.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.38) earnings per share. As a group, equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Wells Fargo & Company increased their target price on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Royal Bank of Canada assumed coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an "outperform" rating and a $65.00 price objective on the stock. Sanford C. Bernstein began coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $42.00 price target on the stock. UBS Group upgraded shares of Tandem Diabetes Care to a "hold" rating in a research report on Friday, August 2nd. Finally, Piper Sandler restated an "overweight" rating and set a $55.00 price target (up from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of "Moderate Buy" and an average price target of $54.25.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.